Author

D. Olagnier

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Cell Biology· 1 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Research Focus:chromatin & epigenetic regulation· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

T. B. Poulsen· 4 shared C. K. Holm· 3 shared E. B. Svenningsen· 3 shared M. Idorn· 3 shared S. R. Paludan· 3 shared J. Thyrsted· 2 shared L. Reinert· 2 shared A. Alcami· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

T. B. Poulsen

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

NRF2 activators inhibit influenza A virus replication by interfering with nucleo-cytoplasmic export of viral RNPs in an NRF2-independent manner

F. H. Waqas, M. Shehata, W. A. M. Elgaher, A. Lacour, N. Kurmasheva, F. Begnini, A. E. K. E. Kiib, J. Dahlmann, C. Chen, T. B. Poulsen, S. Merkert, U. Martin, R. Olmer, D. Olagnier, A. Hirsch, , F. Pessler

This paper shows NRF2 activators inhibit influenza A virus by blocking nuclear export of viral RNPs, independent of NRF2 signaling, through interaction with XPO1 and KEAP1.

bioRxiv · Jun 11, 2023Microbiology

Distinct SARS-CoV-2 sensing pathways in pDCs driving TLR7-antiviral vs. TLR2-immunopathological responses in COVID-19

R. M. van der Sluis, L. B. Cham, A. G. Oliver, K. R. Gammelgaard, J. G. Pedersen, M. Idorn, U. Ahmodov, S. S. Hernandez, E. Cemalovic, S. H. Godsk, J. Thyrsted, J. D. Gunst, S. D. Nielsen, J. j. Jorgensen, T. W. Bjerg, , M. R. Jakobsen

The paper shows that pDCs use TLR7 for antiviral responses and TLR2 for inflammatory responses to SARS-CoV-2, with neuropilin-1 inhibiting antiviral IFNs.

bioRxiv · Nov 23, 2021 · PreprintImmunology

The synthetic triterpenoids CDDO-TFEA and CDDO-Me, but not CDDO, are potent BACH1 inhibitors

L. Casares, R. Moreno, M. Higgins, S. D. Naidu, G. Neill, L. Cassin, A. E. Kiib, E. B. Svenningsen, T. Honda, T. B. Poulsen, A. T. Dinkova-Kostova, D. Olagnier, L. de la Vega

This study identifies CDDO-derivatives as BACH1 inhibitors, explaining their higher potency as HMOX1 inducers compared to CDDO.

bioRxiv · Oct 29, 2021 · PreprintCell Biology

Identification of SARS-CoV2-mediated suppression of NRF2 signaling reveals a potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate

D. Olagnier, E. Farahani, J. Thyrsted, J. B. Cadanet, A. Herengt, M. Idorn, A. Hait, B. Hernaez, A. Knudsen, M. B. Iversen, M. Schilling, S. E. Jorgensen, M. Thomsen, L. Reinert, M. Lappe, , C. K. Holm

The paper identifies NRF2 agonists 4-OI and DMF as inhibitors of SARS-CoV2 replication and inflammatory responses, effective against multiple viruses.

bioRxiv · Jul 16, 2020Microbiology

Ionophore antibiotic X-206 is a potent and selective inhibitor of SARS-CoV-2 infection in vitro

E. B. Svenningsen, J. T. Jensen, J. Blay-Cadanet, H. Liu, S. Lin, J. M. Villameriel, D. Olagnier, M. Idorn, S. R. Paludan, C. K. Holm, T. B. Poulsen

This study identifies X-206, a polyether ionophore antibiotic, as a potent and selective inhibitor of SARS-CoV-2 infection in vitro with high selectivity and sub-nM efficacy.

bioRxiv · Jun 14, 2020Pharmacology & Toxicology